Hypermarcas (OTCMKTS:HYPMY – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.44 and traded as low as $3.39. Hypermarcas shares last traded at $3.95, with a volume of 67,913 shares traded.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Hypermarcas presently has a consensus rating of “Buy”.
View Our Latest Analysis on Hypermarcas
Hypermarcas Trading Down 26.9%
The business has a fifty day simple moving average of $4.67 and a 200 day simple moving average of $4.44. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 7.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86.
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. As a group, equities analysts anticipate that Hypermarcas will post 0.51 EPS for the current year.
About Hypermarcas
Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.
Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.
The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.
Further Reading
- Five stocks we like better than Hypermarcas
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
